New myostatin drug coming Bimagrumab

Bimagrumab

Bimagrumab is a monoclonal antibody that blocks activin II receptors, preventing the activity of myostatin and other negative skeletal muscle regulators that show increased muscle weight and muscle hypertrophy after treatment

In this phase 2 randomized clinical trial, ActRII blockade with bimagrumab led to significant loss of FM, gain in LM, and metabolic improvements during 48 weeks in patients with overweight or obesity who had type 2 diabetes. ActRII pathway inhibition may provide a novel approach for the pharmacologic management of excess adiposity and accompanying metabolic disturbances.

In this study, 48 weeks of exposure to bimagrumab, an antibody inhibitor of ActRII, was safe and effective for treating the excess adiposity and metabolic disturbances of adult patients with obesity and type 2 diabetes. While antibody blockade or knockout of ActRII in animal models is accompanied by marked increases in skeletal muscle mass, this study confirms that inhibition of this receptor in human participants leads to not only increases in lean mass but profound decreases in body fat, along with improvements in glycemic control. Inhibition of ActRII may provide a novel pathway for the pharmacologic management of excess adiposity and accompanying metabolic disturbances.

These pharmaceutical myostatin inhibitors are interesting. Not available yet in any meaningful form. We are watching. For now Primo, Anavar, and GH are the practical tools for clean muscle with minimal catabolism.

The Bimagrumab trial data is interesting but effect size in non-obese individuals is modest. The mechanism is solid, ActRIIB pathway inhibition, but real-world application for a healthy person with normal myostatin levels is debatable.

Bimagrumab is an anti-ActRIIB antibody. Phase 2b in obese adults: 20.5% fat mass reduction and 3.6% lean mass gain at 48 weeks. The dual effect, losing fat while gaining muscle, is mechanistically unique. As a monoclonal antibody it cannot be synthesised in a home laboratory and currently has no approved indication. Regulatory approval may come within 5 years based on the trial trajectory.

The bimagrumab mechanism is quite elegant from a pharmacological standpoint. Anti-activin type II receptor antibody blocks not just myostatin but also GDF-11 and activin A signaling, all of which promote muscle catabolism. The phase 2 results showing simultaneous lean mass gain and fat loss in a non-exercising population are remarkable. Combined with resistance training the effect size would theoretically be substantially larger.